. 2009 Aug 10;1:89–97.

Table 2.

Prevention of acute chemotherapy-induced nausea and vomiting: results of clinical trials with palonosetron

Reference	No. of patients	Emetic risk category	Antiemetic regimen on Day 1	CR (%)	Emesis-free patients (%)
Randomized studies
Gralla 2003²⁵	189	MEC	Palo 0.25 mg	81	85
Gralla 2003²⁵	189	MEC	^aDex 20 mg
Eisenberg 2003²⁶	189	MEC^b	Palo 0.25 mg	64	72
Eisenberg 2003²⁶	189	MEC^b	^aDex 20 mg
Aapro 2006³⁴	223	HEC	Palo 0.25 mg	59	68
Aapro 2006³⁴	223	HEC	^aDex 20 mg
Yu 2009³⁵	104	HEC	Palo 0.25 mg	83	NA
Saito 2009²⁷	239	MEC (AC-based)	Palo 0.75 mg	69	NA
Saito 2009²⁷	239	MEC (AC-based)	Dex 16 mg
Saito 2009²⁷	316	HEC	Palo 0.75 mg	80	NA
Saito 2009²⁷	316	HEC	Dex 16 mg
Nonrandomized studies
Grote 2006⁴³	58	MEC^c	Palo 0.25 mg	88	93
			Dex 12 mg
			Apr 125 mg
Navari 2007⁴⁷	32	MEC	Palo 0.25 mg	97	97
			Dex 8 mg
			Olanzapine 10 mg
Giuliani 2008⁴⁰	85	MEC	Palo 0.25 mg	99	99
Giuliani 2008⁴⁰	85	MEC	Dex 8 mg
Grunberg 2008⁴⁵	41	MEC	Palo 0.25 mg	76	100
			Dex 20 mg
			Apr 285 mg
Lorusso 2009³⁹	35	HEC	Palo 0.25 mg	86	NA
Lorusso 2009³⁹	35	HEC	Dex 20 mg

Corticosteroid given at the discretion of the investigator;

the cohort includes 120 patients receiving AC-based chemotherapy;

the cohort includes 24 patients receiving AC-based chemotherapy.

Abbreviations: CR, complete response; MEC, moderately emetogenic chemotherapy; HEC, highly emetogenic chemotherapy; AC, anthracycline and cyclophosphamide; Palo, palonosetron, Dex, dexamethasone; Apr, aprepitant; NA, not available.